Xu Rong, Hao Yitong, Liu Yahui, Ji Bai, Tian Weibo, Zhang Wei
Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Life Sci. 2025 Feb 15;363:123395. doi: 10.1016/j.lfs.2025.123395. Epub 2025 Jan 12.
Lactylation, a novel form of lactate-mediated protein post-translational modification (PTM), has been identified as a crucial regulator of gene expression and protein function through the modification of both histone and non-histone proteins. Liver disease is frequently characterized by a reprogramming of glucose metabolism and subsequent lactate accumulation. Recent research has implicated lactylation in a diverse array of hepatic pathologies, including liver injury, non-alcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma. Consequently, lactylation has emerged as a pivotal regulatory mechanism in liver disease pathogenesis. This review aims to elucidate the intricate regulatory and functional mechanisms underlying lactylation, synthesize recent advancements in its role in various liver diseases, and highlight its potential as a therapeutic target for future interventions in hepatic disorders.
乳酰化是乳酸介导的蛋白质翻译后修饰（PTM）的一种新形式，已被确定为通过修饰组蛋白和非组蛋白对基因表达和蛋白质功能起关键调节作用。肝脏疾病的特征通常是葡萄糖代谢重编程及随后的乳酸积累。最近的研究表明，乳酰化与多种肝脏疾病有关，包括肝损伤、非酒精性脂肪性肝病、肝纤维化和肝细胞癌。因此，乳酰化已成为肝脏疾病发病机制中的关键调节机制。本综述旨在阐明乳酰化背后复杂的调节和功能机制，综合其在各种肝脏疾病中作用的最新进展，并强调其作为肝脏疾病未来干预治疗靶点的潜力。
